Breast and axillary marking in the neoadjuvant setting: survey results from experts of the Brazilian society of mastology
- PMID: 39445065
- PMCID: PMC11496257
- DOI: 10.3389/fonc.2024.1393417
Breast and axillary marking in the neoadjuvant setting: survey results from experts of the Brazilian society of mastology
Abstract
Introduction/objectives: The precise location of the tumor site is essential for the success of surgical treatment. Neoadjuvant chemotherapy (NAC) is a challenge for preoperative tumor and node localization. Thus, the knowledge and attitudes of the affiliated members of the Brazilian Society of Mastology (SBM) regarding breast and axilla marking were evaluated and a consensus regarding management and treatment was reached.
Methods: This was an online survey conducted between June and December 2022. All 1,742 active mastologists affiliated to the SBM were invited anonymously. The online form contained 28 objective questions, of which 22 were formulated on a Likert scale. These questions addressed relevant aspects related to breast and axilla marking in the neoadjuvant setting. Responses that reached 70% agreement were considered consensual. Statistical analysis was performed using the SPSS program version 26.0. Post hoc analysis was performed when appropriate and the significance level was set at p < 0.05. Polychoric regression analyses were conducted using `VGAM` package.
Results: In total, 468 mastologists answered the questionnaire (26.8%), with a predominance of professionals aged between 40-49 years (32.1%). Most professionals were board-certified (84,8%). The indication of tumor marking in the breast prior to NAC was consensual (96.4%) and the metal clip was the preferred method (69.7%). There was no consensus regarding the indication of pre-NAC histologically positive lymph node marking (49.8% disagree and 42.8% agree). However, there was consensus that the clinical and imaging evaluation was insufficient for staging the axilla as N1 (71.6%). The contraindication of breast and node marking in T4b tumors (71.2%) was consensual. There was consensus on the indication of sentinel lymph node biopsy (SLNB) for initially cN1 (92.3%) or cN2 (72.7%) tumors that became cN0 after NAC, with 67.5% opting for dual staining with technetium and patent blue. When <3 lymph nodes were retrieved 41.0% of mastologists performed axillary lymphadenectomy. Among the 28 questions, consensus was reached on only 11 (39.3%).
Conclusion: The indication of pre-NAC breast marking is consensual among Brazilian mastologists, although axillary nodal marking is not. There is a great divergence of attitudes among Brazilian surgeons in relation to the many issues related to pre-NAC breast and axilla marking.
Keywords: breast neoplasm; breast tumor markers; consensus development conferences; neoadjuvant therapy; sentinel lymph node.
Copyright © 2024 Couto, Hassan, Steinmacher, Pessoa, Millen, Zerwes, Cavalcante, Tosello, Novita, Machado Badan, Esteves Francisco, Soares, Budel, Fernandes Chala, Fernandes, Freitas-Junior, Oliveira, Budel and Mattar.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.J Surg Oncol. 2020 Nov;122(6):1247-1251. doi: 10.1002/jso.26104. Epub 2020 Jul 7. J Surg Oncol. 2020. PMID: 33045117
-
Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain.Clin Transl Oncol. 2023 May;25(5):1463-1471. doi: 10.1007/s12094-022-03049-6. Epub 2022 Dec 31. Clin Transl Oncol. 2023. PMID: 36586064
-
Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.JAMA Surg. 2022 Nov 1;157(11):991-999. doi: 10.1001/jamasurg.2022.3907. JAMA Surg. 2022. PMID: 36069889 Free PMC article.
-
Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus.Eur J Surg Oncol. 2024 Jul;50(7):108351. doi: 10.1016/j.ejso.2024.108351. Epub 2024 Apr 24. Eur J Surg Oncol. 2024. PMID: 38701582
-
Refining the Performance of Sentinel Lymph Node Biopsy Post-neoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice.Anticancer Res. 2016 Apr;36(4):1461-71. Anticancer Res. 2016. PMID: 27069121 Review.
References
-
- Shah C, Hobbs BP, Vicini F, Al-Hilli Z, Manyam BV, Verma V, et al. . The diminishing impact of margin definitions and width on local recurrence rates following breast-conserving therapy for early-stage invasive cancer: A meta-analysis. Ann Surg Oncol. (2020) 27:4628–36. doi: 10.1245/s10434-020-08878-9 - DOI - PubMed
-
- Garzotto F, Comoretto RI, Michieletto S, Franzoso G, Lo Mele M, Gregori D, et al. . Preoperative non-palpable breast lesion localization, innovative techniques and clinical outcomes in surgical practice: A systematic review and meta-analysis. Breast. (2021) 58:93–105. doi: 10.1016/j.breast.2021.04.007 - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous